Rangwala Reshma 4
4 · Karyopharm Therapeutics Inc. · Filed Mar 3, 2026
Insider Transaction Report
Form 4
Rangwala Reshma
EVP & Chief Medical Officer
Transactions
- Sale
Common Stock
[F1]2026-03-02$9.41/sh−5,066$47,669→ 56,739 total
Footnotes (1)
- [F1]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
Signature
/s/ Nancy Smith as Attorney-in-Fact for Reshma Rangwala|2026-03-03